Arbutus biopharma announces claim construction ruling in its ongoing patent infringement lawsuit against moderna

Warminster, pa., april 04, 2024 (globe newswire) -- arbutus biopharma corporation (nasdaq: abus), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for people with chronic hepatitis b virus (chbv) infection, today issued the following statement regarding the claim construction ruling of the u.s. district court for the district of delaware in the lawsuit brought by arbutus and its licensee genevant sciences (plaintiffs) against moderna, inc. and a moderna affiliate seeking damages for infringement of u.s. patent nos. 8,058,069, 8,492,359, 8,822,668, 9,364,435, 9,504,651, and 11,141,378 in the manufacture and sale of mrna-1273, moderna's vaccine for covid-19.
ABUS Ratings Summary
ABUS Quant Ranking